Strengthening of strategic option license agreement to cover additional novel ADC targets Copenhagen, Denmark, May 30th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes Strong overexpression in tumors combined with low expression levels in normal human tissues makes uPARAP an attractive candidate for therapeutic targeting of sarcomas by...
Series A Financing extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR Funds will be used to ensure broad pan-sarcoma development of lead ADC assetuPARAP and to further advance second ADC...
Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Copenhagen, Denmark,...
GlyTherix Ltd (“GlyTherix”), an Australian immune-oncology company today announced an MTA & Option License with Adcendo ApS (“Adcendo”), a Danish biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Copenhagen, Denmark, May...